Abstract
The contribution of ?3-AR activation towards ischemiareperfusion (IR) damage largely depends on the disease stage, severity, experimental model as well as drug specificities which should be considered when investigating ?3-AR pharmacology for potential therapeutic applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have